INZY Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.37%, SMA50 40.19%, SMA200 43.56%). The stock’s 14-day RSI is 82.7 (overbought), while the ATR of 0.05 points to moderate volatility. The stock remains hovering near 52-week lows, trading -35.9% below its high and over 454.79% above its low.

The stock is currently mid-range between its 52-week high and low $0.72 and $6.24. With a market capitalization of about $258.25 million, Inozyme Pharma, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.29). Key stats such as the average daily volume over the past year has been around 2.26 million shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Inozyme Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Douglas A. Treco, the company employs approximately 67 people and listed since July 24, 2020. Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases.

Inozyme Pharma, Inc. generated EPS of -$1.68 over the past year. Five-year average earnings growth is -13.98%. Wall Street analysts project EPS growth of 17.79% annually over the next five years. The latest quarter delivered EPS of -$0.44. The next quarter is forecast at -$0.38. Next year's EPS is expected at $0.21. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $4.00. The high target offers 0.0% upside. The low target suggests 0.0% downside. The mean target is $4.00. This offers 0.0% upside. Inozyme Pharma, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 05, 2025, missed forecasts by 22.22%. The prior quarter beat by 2.33%. Over the last six quarters, Apple has recorded several small beats. These include 8.57% in May 07, 2024.

Inozyme Pharma, Inc. has 64.56 million shares outstanding. The public float is 30.01 million shares, elevated short interest at 6.16% of float. This equals 3.68 million shares. The short ratio is 0.75 days. Institutional investors hold 95.49% of the float. Insiders own 1.26%. ENRIGHT PATRICK G holds 4.17 million shares, Longitude Capital Partners III, LLC has 4.17 million shares and Pivotal bioVenture Partners Fund I U.G.P., Ltd has 2.66 million shares.

Inozyme Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.41. This means the shares are trading below this model’s fair value.

Inozyme Pharma, Inc. trades at a P/E ratio of -4.67, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 8.09 trading at moderately above to book value. The P/FCF stands at -5.34, also above market averages.

Our AI price prediction model suggests that Inozyme Pharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.5%, with price expected at $4.62 by July 14, 2025, within a range of $3.57 to $5.57 3-Month Outlook: Projected rise of 444.0%, reaching $21.76 by September 26, 2025, with a range of $21.12 to $22.93. 1-Year Outlook: Projected gain of 260.75%, with price at $14.43 by June 30, 2026, within a range of $0.00 to $32.34.

Inozyme Pharma, Inc. (NASDAQ:INZY) shares are up 44.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Inozyme Pharma, Inc. trading at a premium to the broader market with a P/E of -4.67. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $17.65, suggesting 341.25% upside. Our AI forecast model points to short-term strength (15.5% over two weeks), a medium-term rise (444.0% over three months), and a longer-term gain (260.75% over one year), with expected trading ranges indicating moderate volatility.